Ralph Toelg

Showing 1-10 of 10 articles

Outcomes of rotational atherectomy versus modified balloon angioplasty in severely calcified coronary lesions based on target lesion location: a post hoc analysis of the PREPARE-CALC randomised trial

Rheude T, Toelg R, Byrne R, Allali A, Wiebe J, Sulimov D, Voll F, Cassese S, Richardt G, Kastrati A, Abdel-Wahab M

July 17, 2020 | 10.4244/EIJ-D-19-00488

Coronary interventions

Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial

Haude M, Ince H, Toelg R, Lemos P, von Birgelen C, Christiansen E, Wijns W, Neumann F, Eeckhout E, Garcia-Garcia H, Waksman R

February 7, 2020 | 10.4244/EIJ-D-18-01000

Coronary interventions

BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months

Saito S, Toelg R, Witzenbichler B, Haude M, Masotti M, Salmeron R, Witkowski A, Uematsu M, Takahashi A, Waksman R, Slagboom T

December 6, 2019 | 10.4244/EIJ-D-18-01214

Coronary interventions

Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III

Haude M, Ince H, Kische S, Abizaid A, Toelg R, Lemos P, Van Mieghem N, Verheye S, von Birgelen C, Christiansen E, Wijns W, Garcia-Garcia H, Waksman R

July 20, 2017 | 10.4244/EIJ-D-17-00254

Interventions for valvular disease

Impact of femoral artery puncture using digital subtraction angiography and road mapping on vascular and bleeding complications after transfemoral transcatheter aortic valve implantation

El-Mawardy M, Schwarz B, Landt M, Sulimov D, Kebernik J, Allali A, Becker B, Toelg R, Richardt G, Abdel-Wahab M

January 20, 2017 | 10.4244/EIJ-D-15-00412

Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELUX registry

Toelg R, Merkely B, Erglis A, Hoffmann S, Bruno H, Kornowski R, Slagboom T, Naber C, Witzenbichler B, Graf K, Richardt G, Hehrlein C

September 28, 2014 | 10.4244/EIJV10I5A102

Comparison of bivalirudin and heparin in patients undergoing rotational atherectomy: a subanalysis of the randomised ROTAXUS trial

Akin I, Khattab A, Buettner H, Toelg R, Geist V, Neumann F, Richardt G, Abdel-Wahab M

August 19, 2014 | 10.4244/EIJV10I4A79

Stuck rotablator: the nightmare of rotational atherectomy

Sulimov D, Abdel-Wahab M, Toelg R, Kassner G, Geist V, Richardt G

June 28, 2013 | 10.4244/EIJV9I2A41

Determination of haemodynamic significance of intermediate coronary lesions using three-dimensional coronary reconstruction

Saad M, Toelg R, Khattab A, Kassner G, Abdel-Wahab M, Richardt G

November 15, 2009 | 10.4244/EIJV5I5A93

Relationship between cardiovascular risk as predicted by established risk scores and coronary artery plaque composition as detected by virtual histology intravascular ultrasound analysis: the PREDICT pilot study

Abdel-Wahab M, Khattab A, Liska B, Toelg R, El-Hammady W, Farag N, Geist V, Ramzy A, Richardt G

January 20, 2008

1

Latest news

EAPCI/ACVC consensus on pVADs, coronary physiology mini focus, a new analysis from the COAPT trial, patient selection for tricuspid interventions and more…

Joint EAPCI/ACVC expert consensus document on pVADs

Beyond ischaemia: is there a place for physiologic and anatomic evaluations of coronary lesions?

Gilles Montalescot

This Week's JAA's: Principles and Pitfalls in CFT, Brachial access for PCI....

Coronary flow capacity: where to next?

Nils P. Johnson

EuroIntervention's new impact factor!

STATE OF THE ART

Completeness of Revascularisation in ACS Patients with Multivessel Disease

Valeria Paradies et al.

Valvular disease